Navigation Links
Olympus Biotech Names Oliver Burckhardt to President North America
Date:5/23/2011

HOPKINTON, Mass., May 23, 2011 /PRNewswire/ -- Olympus Biotech, an Olympus Corporation company, today announced the appointment of Oliver Burckhardt to the position of president of Olympus Biotech Corporation. In his new role, Mr. Burckhardt will lead the company's North American business and focus on expanding opportunities for the emerging regenerative medicine market. Mr. Burckhardt will also become a member of the Olympus Biotech Board of Directors.

"With nearly 20 years in the medical device industry, Oliver's extensive knowledge of the industry and global leadership experience will prove invaluable as we continue to grow Olympus Biotech," said Hitoshi Mizuno, CEO Olympus Biotech Corporation. "We look forward to benefiting from his immense expertise as we continue to lead the creation of this dynamic new field of medicine."

Before joining Olympus Biotech, Mr. Burckhardt most recently served as the international president and CEO of Scient'x Corp in Paris, France, where his strategic vision redefined the company's direction and resulted in double-digit growth. Mr. Burckhardt also served as president of Orthofix, Inc., where he was responsible for the global spine business unit. Prior to that, Mr. Burckhardt spent nine years with Aesculap, Inc. in various sales and marketing positions, including vice president of sales and marketing for the Aesculap Spine division in the United States.

"The Vision of Olympus Biotech to advance into regenerative medicine is the next logical step in the treatment of many medical pathologies and conditions. I am excited about the overall strategic thinking and the assets that are already in place, within Olympus, which represent a perfect starting point for this future oriented strategy," said Mr. Burckhardt. He added, "I look forward to joining the talented team at Olympus Biotech and leveraging my experience in the industry to generate further growth and success."

About Olympus Biotech Corporation

Olympus Biotech was established in December, 2010 as a wholly owned company of Olympus Corporation. The vision of Olympus Biotech is to improve the patient Quality of Life by developing and distributing Regenerative Medicine that stimulate the intrinsic healing capacity in the living body by the technological development of growth factors and biomaterials.

Media Contact:
Jessica Nelson
Kwittken & Company
(646) 747-7141
jnelson@kwitco.com


'/>"/>
SOURCE Olympus Biotech Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Gumz to Retire as President and CEO of Olympus Corporation of the Americas
2. Stryker Completes Sale of OP-1 for use in Orthopaedic Bone Applications to Olympus
3. Stryker Announces Definitive Agreement to Sell OP-1 for Use in Orthopaedic Bone Applications to Olympus
4. Olympus Launches 2011 National Innovation Awards Program
5. Olympus America Licenses Digital Pathology Patents to BioImagene, Inc.
6. Omnyx Licenses Olympus Digital Pathology Patents
7. Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device
8. Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
9. Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
10. Centocor Ortho Biotech Products, L.P. Voluntarily Withdraws NDA for Trabectedin
11. Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Business Report" report to their offering. ... This report analyzes the worldwide markets for Dental Implants ... Canada , Japan , ... , and Rest of World. Annual estimates and ...
(Date:3/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The IPF pipeline is very strong with a total of 97 drug ... Biogen and Sanofi are involved in the development of the IPF therapeutics. ... in Phase III stage, 15 are in Phase II stage, 12 are ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , ... are provided for the period 2015 through 2022. Also, a six-year historic ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. Angel Vitamins, a 5-year-old ... rebranding effort. This includes the introduction of new packaging and messaging, as well ... we learned that a simple, proactive approach to wellness is important to vitamin ...
(Date:3/27/2017)... RICHEY, Fla. (PRWEB) , ... March 27, 2017 ... ... drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of ... Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on ...
(Date:3/26/2017)... Ohio (PRWEB) , ... March 26, 2017 , ... ... doctors worldwide to receive the RealSelf 100 Award, a prestigious award honoring the ... cosmetic procedures and to find and connect with doctors and clinics. , In ...
(Date:3/24/2017)... ... 2017 , ... Clean Earth, Inc., a leader in providing ... materials announced today the acquisition of privately owned AERC Recycling Solutions ... facilities and a vast array of additional technologies, services, and new markets to ...
(Date:3/24/2017)... ... 24, 2017 , ... Infectious disease affects billions of people ... States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting Infection” ... strategies for the healthcare community to help decrease the number of completely preventable ...
Breaking Medicine News(10 mins):